NL
DE
During the lustrum congress of the Dutch Society of Clinical Chemistry, the ErasmusMC/Radboudumc team led by medical immunologist dr. Hans Jacobs (theme Cancer development and immune defence) was awarded the Science & Innovation Award. His team pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma.
Sensitive blood-test as patient-friendly alternative for bone marrow-based cancer monitoring
Funded by KWF an international team of researchers, led by the Radboudumc and the Erasmus MC, have developed a novel technique for the ultra-sensitive assessment of minimal residual disease (MRD) in blood of patients with multiple myeloma using mass spectrometry. In a series of publications they have shown that the test can be applied to all myeloma patients and that that their blood-based method performs equally well compared to MRD-evaluation on bone marrow.
The jury praised the innovative proteogenomic methods that were used as a solution to an urgent unmet clinical need. In collaboration with clinicians, patient-organizations and industry, the researchers develop personalized blood-diagnostics as a patient-friendly alternative to monitor MRD in myeloma patients.
“This Science & Innovation Award is a great appreciation of our team effort in the past 5 years” says dr. Jacobs. “We have created personalized diagnostics that can make a significant health impact for cancer patients. We still have a long way to go before patients will benefit from our work. This award further inspires our team in our endeavor towards actual implementation of our methodology in clinical practice”.
Read a selection of the key publications of the MS-MRD blood test here.
Read more about the Dutch Society of Clinical Chemistry and the Dutch Cancer Society.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Michiel Vermeulen and Klaas Mulder receive funding from ZonMw for a collaborative project using stem cell-based models
15 July 2021 Michiel Vermeulen and Klaas Mulder, theme Cancer development and immune defense, receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis. read more
ZonMw Open Competition Grant for Annemiek van Spriel and Piet Gros
15 June 2021 Annemiek van Spriel, theme cancer development and immune defense, together with Piet Gros, Dept. of Chemistry, Utrecht University obtained a ZonMw Open Competition Grant to investigate IL-6 receptor structure and signalling in tumor cells. read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy
15 April 2021 The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period. read more
HFSP Grant for Johannes Textor
30 March 2020 Johannes Textor, theme Cancer development and immune defense, has been awarded a program grant of 1 million US dollars by The Human Frontier Science Program (HFSP) to investigate how T cells navigate extremely dense environments using experiments, modeling and methods from pedestrian dynamics. read more
NWO open call GROOT grant for Michiel Vermeulen
24 February 2020 Michiel Vermeulen, theme Cancer development and immune defense, received a 300,000 EUR grant within the NWO-GROOT consortium. He will use mass spectrometry-based proteomics and interaction proteomics applications to study proteome and gene expression dynamics during early C. Elegans development. read more
